Lancing Device Comparison Study
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01740778|
Recruitment Status : Completed
First Posted : December 4, 2012
Last Update Posted : December 4, 2012
|Condition or disease|
|Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2|
A low-pain lancing is being developed code name Aurora) for use with a 33g proprietary lancet (code name Velvet). This study evaluates the pain associated with finger lancing using this device and compares that pain to other commercially available lancing devices and associated lancets.
All lancets used in the study are currently commercially available except the Facet 33g lancet, which is a prototype version of commercially available lancets.
The Roche Multiclix, Roche Softclix, One Touch Comfort and Bayer Microlet 2 lancing devices are all commercially available.
The Aurora Lancing Device is effective in obtaining a sufficient blood sample for performing an accurate blood glucose measurement; and the benefits of using the Aurora Lancing Device outweighs any residual risks associated with the product. Literature concerning blood glucose testing was researched by using popular medical databases such as pubmed.gov, diabeteshealth.com, clinicaltrial.gov and search terms lancing device, clinical study, blood volume and pain. Using other popular search engines such as Google was beneficial in helping to support claims concerning safety and efficacy. A commercial database company, NERAC was used as a part of the literature research effort. Our review, together with preliminary in-house bench testing, shows that the Aurora Lancing Device should be able to:
- Obtain enough blood volume for a meter reading that measures blood glucose levels;
- Is as safe as comparative lancing devices currently on the market;
- Produces no more pain than comparative lancing devices currently on the market using a 28 gauge needle; and
- Is representative of "current state of the art" The Aurora Lancing Device uses a 33 gauge, uniquely designed lancet developed under project Velvet. The blood lancet is designed so that it can only be used in the Aurora lancing device. The lancing device features multiple depth settings and includes alternate site test capability. The lancet guidance system is designed to maximize lancet control thereby increasing comfort and reducing pain perception. The Aurora lancing device is comparable to the Roche Softclix and other lancing devices already in commercial distribution. Like Aurora the Roche Softclix lancing device offers diabetics a unique lancet design and precise lancet motion. Roche Softclix uses a 28 gauge lancet and has eleven depth settings as well as alternative site test capability.
|Study Type :||Observational|
|Actual Enrollment :||200 participants|
|Official Title:||Lancing Device Comparison Study|
|Study Start Date :||August 2009|
|Actual Primary Completion Date :||September 2009|
|Actual Study Completion Date :||September 2009|
Study Group 1
Aurora vs. Microlet 2
Study Group 2
Aurora vs. SoftClix
Study Group 3
Aurora vs. One Touch Comfort
Study Group 4
Aurora vs. Multiclix
- Blood Glucose Reading [ Time Frame: 1-1 hour visit during the study ]
During the first part of the study, subjects will test their lancing devices at a depth setting sufficient to provide enough blood volume to trigger the OneTouch® Ultra®Mini blood glucose meter using OneTouch® Ultra® blood glucose test strips.
The second part of the study will generate the pain data associated with the Alternate site testing (AST) will also be performed on the palm of the hand and the forearm with the Aurora device and Velvet 33g lancet.
Each lancing event, in the first portion of the study, is considered successful if at least 2 out of 3 lancing events are successful in producing enough blood to trigger the One Touch® Ultra®Mini blood glucose meter.
- Pain Scale Rating [ Time Frame: 1- 1 hour visit during the study ]
The second part of the study will generate the pain data associated with the Aurora device and Velvet 33g lancet along with the study comparative device. During the second visit, alternate site testing (AST) will also be performed on the palm of the hand and the forearm with the Aurora device and Velvet 33g lancet.
The second portion of the study will compare and report the differences in pain between the device/lancet combinations. Pain will be assessed for each successful fingerstick per the visual analog scale (VAS).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01740778
|Principal Investigator:||Ashley Shemain, MBA||SHEMAIN CONSULTING GROUP, LLC|